AllSci News
EC revokes Hansoh’s aumolertinib approval over data protection breach
The European Commission has revoked the EU marketing authorization for China-based Hansoh Pharmaceutical Group Company Limited’s (HKEX: 3692) aumolertinib...
Celularity raises USD 10m in first tranche of USD 28m recapitalization
New Jersey-based Celularity Inc. (Nasdaq: CELU) has closed an initial tranche of a private placement of senior secured convertible notes and warrants,...
Ligand backs AvenCell CAR-T pipeline with up to USD 47m
Florida-based Ligand Pharmaceuticals (Nasdaq: LGND) has entered a financing agreement with Massachusetts-based AvenCell Therapeutics worth up to USD 47...
Scancell secures USD 25m debt facility from BlackRock to fund iSCIB1+ Phase III melanoma trial
UK-based Scancell Holdings plc (AIM: SCLP) has secured a loan facility of up to USD 25 million from funds and accounts managed by BlackRock to fund the...
Indivior exits Addex partnership, returns GABAB portfolio rights
Geneva-based Addex Therapeutics (Nasdaq: ADXN) has regained full global rights to its GABAB positive allosteric modulator (PAM) portfolio from UK-based...
BigHat Bio raises USD 75m Series C as AI-designed protein therapeutics advance
San Mateo, California-based BigHat Biosciences has raised USD 75 million in a Series C financing to advance its clinical-stage pipeline of AI-designed...
Merck, Eisai win FDA approval for Welireg-Lenvima in advanced RCC
Merck and Eisai announced US FDA approval of Welireg (belzutifan) plus Lenvima (lenvatinib) for adults with advanced renal cell carcinoma with a clear cell...
Novo licenses Nanexa's long-acting injectable platform for obesity and diabetes drugs
Uppsala, Sweden-based Nanexa AB (STO: NANEXA) has entered a global exclusive license and collaboration agreement with Novo Nordisk covering use of its...
Proteomic study finds divergent biological responses to lecanemab treatment
A longitudinal cohort study published in The Lancet Neurology and using Alamar Biosciences (Nasdaq: ALMR) proteomics technology has found that patients with...
XtalPi files first proprietary IND for gut-restricted pan-TRK inhibitor KQTD-126
XtalPi (HKEX: 2228), a Boston- and Shenzhen-based AI and robotics-driven drug discovery company, submitted an Investigational New Drug application to the US...
Lundbeck relocates US headquarters to Greater Boston for innovation hub
H. Lundbeck A/S will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, where the Danish drugmaker plans to establish...
SystImmune clears FDA IND for SI-B037 bispecific using NAM-based toxicology package
Redmond, Washington-based SystImmune, the US subsidiary of Chengdu-based Sichuan Biokin Pharmaceutical, received US FDA clearance of an investigational new...
Elevar wins FDA approval for FGFR2 inhibitor Lyrfigtu
Elevar Therapeutics announced US FDA approval of Lyrfigtu (lirafugratinib), an oral FGFR2 inhibitor for adults with previously treated, unresectable,...
Lilly wins FDA approval for once-weekly basal insulin Onswik
Eli Lilly and Company announced US FDA approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin indicated alongside diet and exercise to...
Viking Therapeutics raises USD 500m to advance VK2735 obesity program
San Diego-based Viking Therapeutics (Nasdaq: VKTX) priced a concurrent public offering of common stock and convertible senior notes totalling USD 500...
The AllSci Brief
Free, systematic R&D and deal news. Daily.